At a glance
- Originator Nonindustrial source
- Mechanism of Action Chitin synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 22 Aug 2000 New profile
- 22 Aug 2000 Preclinical development for Mycoses in South Korea (Unknown route)